Inhibitor Treatment
Inhibitor Treatment - Related Videos
04:00
Modelling Intratumoral Treatment with miRNA Inhibitors: A Method to Analyze the Effect of miRNA Inhibitors on Tumor Growth in Murine Model
0 Views •
2023
This video demonstrates the in vivo delivery of miRNA inhibitors as therapeutic agents against tumor growth in orthotopic mouse models. The intratumoral administration of synthetic miRNA inhibitors or antagomiRs allows them to bind and inhibit endogenous miRNAs, thereby causing mRNA upregulation and suppression of tumor growth.
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
0 Views •
Cited by 6 •
2013
Receptor tyrosine kinases are ectopically expressed in many cancers and have been identified as therapeutic targets in acute leukemia. This manuscript describes an efficient strategy for pre-clinical evaluation of tyrosine kinase inhibitors for the treatment of acute leukemia.
01:28
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
0 Views •
2024
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH). Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:52
Eukaryotic Transcription Inhibitors
0 Views •
2020
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells. Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
0 Views •
Cited by 2 •
2024
This study illustrates the methodological potential of combining Yttrium-90 Trans-Arterial Radioembolization (Y-90 TARE) with an anti-PD-1 monoclonal antibody as an effective neoadjuvant strategy leading to hepatectomy in hepatocellular carcinoma (HCC) patients with a high initial recurrence risk. It emphasizes the safety, feasibility, and step-by-step procedural guidance of this approach.
FAQs
The outcome depends on more than whether a compound is present. Dose determines how strongly target activity is reduced, while treatment timing affects which stage of infection or immune activation is observed. Target selectivity helps distinguish effects caused by the intended molecular interaction from broader pathway changes. Together, these variables shape interpretation of inhibitor-treatment experiments.
An inhibitor can be directed toward a pathogen-associated process or a host process. Blocking pathogen replication or entry tests whether that microbial step is required, whereas reducing immune-cell activation examines how host signaling contributes to disease or inflammation. This distinction lets researchers compare antimicrobial strategies with host-directed approaches and connect molecular effects to host-pathogen interactions.
Changes produced by inhibitor treatment can reveal pathway order and disease mechanism. If reducing one enzyme, receptor, or signaling pathway alters replication, entry, immune activation, or inflammation, the result identifies that target as functionally connected to the process being studied. Such evidence can support evaluation of targets for more precise interventions, without treating inhibition alone as proof of clinical suitability.
A basic study begins by selecting a defined enzyme, receptor, protein, or signaling pathway linked to the research question. Researchers then apply an appropriate inhibitor under specified dose and timing conditions and examine the relevant process, such as microbial replication, entry, or immune-cell activation. Comparing these outcomes helps determine whether target reduction changes the experimental system.
Inhibitor treatment is useful when the goal is to separate microbial activity from host responses. In infection studies, researchers can examine whether limiting entry or replication changes the interaction, while immunology experiments can test whether reducing immune-cell activation limits excessive inflammation. The same strategy therefore supports both mechanistic experiments and assessment of potential antimicrobial or host-directed therapies.
Results are interpreted by relating the observed change to the selected target, dose, timing, and degree of selectivity. A reduced infection-related or immune-related outcome may indicate that the targeted process contributes to the system, whereas differing effects under other conditions can clarify when that process matters. These comparisons can reveal disease mechanisms and guide safer, more precise target selection.